Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

A highly significant association between the categorical PD-L1 TPS assessed by IHC and the continuous GEP-derived PD-L1 (CD274) was identified ( p = 0.00013).

also in 132,142 other papers

The increased rate of DCB in patients with PD-L1 ≥1% did not reach statistical significance ( Figure 2 ).

also in 111,027 other papers